Papers - MORITAKE Hiroshi
-
EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice Reviewed
Yamada K., Ohno T., Aoki H., Semi K., Watanabe A., Moritake H., Shiozawa S., Kunisada T., Kobayashi Y., Toguchida J., Shimizu K., Hara A., Yamada Y.
Journal of Clinical Investigation 123 ( 2 ) 600 - 610 2013.2
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Journal of Clinical Investigation
Clear cell sarcoma (CCS) is an aggressive soft tissue malignant tumor characterized by a unique t(12;22) translocation that leads to the expression of a chimeric EWS/ATF1 fusion gene. However, little is known about the mechanisms underlying the involvement of EWS/ATF1 in CCS development. In addition, the cellular origins of CCS have not been determined. Here, we generated EWS/ATF1-inducible mice and examined the effects of EWS/ATF1 expression in adult somatic cells. We found that forced expression of EWS/ATF1 resulted in the development of EWS/ATF1-dependent sarcomas in mice. The histology of EWS/ATF1-induced sarcomas resembled that of CCS, and EWS/ATF1-induced tumor cells expressed CCS markers, including S100, SOX10, and MITF. Lineage-tracing experiments indicated that neural crest-derived cells were subject to EWS/ATF1-driven transformation. EWS/ATF1 directly induced Fos in an ERK-independent manner. Treatment of human and EWS/ATF1-induced CCS tumor cells with FOS-targeted siRNA attenuated proliferation. These findings demonstrated that FOS mediates the growth of EWS/ATF1-associated sarcomas and suggest that FOS is a potential therapeutic target in human CCS.
DOI： 10.1172/JCI63572
-
Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia Reviewed
Moritake H, Kamimura S, Kojima H, Shimonodan H, Harada M, Sugimoto T, Nao-I N, Nunoi H
Pediatr Blood Cancer 60 ( 2 ) 329 - 331 2013.2
Authorship：Lead author Publishing type：Research paper (scientific journal)
-
Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia. Reviewed
Moritake H.＊, Kamimura S., Kojima H., Shimonodan H., Harada M., Sugimoto T., Nao-I N., Nunoi H
Pediatric Blood and Cancer 60 ( 2 ) 329 - 331 2013.2
Language：English Publishing type：Research paper (scientific journal)
-
Characteristics of Illness Perception and Psychosocial Adaptation of Survivors of Childhood Cancer Reviewed
TAKEI Yuko, OGATA Akiko, OZAWA Miwa, MORITAKE Hiroshi, HIRAI Kei, MANABE Atsushi, SUZUKI Shin-ichi
Japanese journal of behavior therapy 39 ( 1 ) 23 - 33 2013.1
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Japanese Association of Behavioral and Cognitive Therapies
The purpose of the present study was to examine the correlation between perceived illness experiences and psychosocial adaptation in adolescent childhood cancer survivors. The participants, 21 youth (7 boys, 14 girls; average age 15.8 years, SD 2.1) who were cancer patients attending pediatric outpatient clinics, were asked to participate in a semi-structured interview and complete the Pediatric Quality of Life (QOL) Inventory. The results indicated that psychosocial daily difficulties influenced their illness perception. Although the results were not statistically significant, positive perception might correlate positively with QOL, and negative perception or a despairing attitude might correlate negatively with QOL. Future research should investigate those influences in a quantitative study.
-
Efficacy of Temozolomide in a Central Nervous System Relapse of Neuroblastoma with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation Reviewed
Yamada A., Moritake H.＊, Shimonodan H., Yokogami K., Takeshima H., Nunoi H
Journal of Pediatric Hematology and Oncology 35 ( 1 ) e38 - e41 2013.1
Language：English Publishing type：Research paper (scientific journal)
-
Treatment outcome of non-Hodgkin lymphoma in childhood : KYCCSG NHL-89, 96 Reviewed
FUKANO Reiji, SUMINOE Aiko, MATSUZAKI Akinobu, INADA Hiroko, NAGATOSHI Yoshihisa, ISHII Eiichi, NAKAYAMA Hideki, KAWAKAMI Kiyoshi, MORITAKE Hiroshi, YANAI Fumio, ITONAGA Nobuyoshi, SUENOBU Soichi, KIKUCHI Masahiro, OKAMURA Jun, KAWANO Yoshifumi
Rinsho Ketsueki 53 ( 11 ) 1898 - 1905 2012.11
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Hematology
Two consecutive treatment protocols, NHL-89 and NHL-96, for pediatric diffuse large cell lymphoma (DLC) and lymphoblastic lymphoma (LBL) were conducted between March 1989 and December 2004 by Kyushu-Yamaguchi Children's Cancer Study Group. Forty-two patients (DLC: 15, LBL: 27) and 34 patients (DLC: 8, LBL: 26) were enrolled in NHL-89 and NHL-96, respectively. DLC patients received induction therapy of high-dose methotrexate (MTX) followed by repeated administration of intermediate MTX. LBL patients received a 4-drug induction followed by intensification, consolidation with cranial radiotherapy (15 to 24Gy), and maintenance. The maintenance phase consisted of multiple drug treatment; including prednisolone, vincristine, cyclophosphamide, and 6-mercaptopurine. With a median follow-up of 150 months for NHL-89 and 90.5 months for NHL-96, the estimated event-free survival at 5 years are 76.2±6.6% and 67.7±8.0%, respectively. Both studies improved the prognosis of DLC and LBL over our previous study of NHL-858.
-
[Treatment outcome of non-Hodgkin lymphoma in childhood: KYCCSG NHL-89, 96]. Reviewed
Fukano R., Suminoe A., Matsuzaki A., Inada H., Nagatoshi Y., Ishii E., Nakayama H., Kawakami K., Moritake H., Yanai F., Itonaga N., Suenobu S., Kikuchi M., Okamura J., Kawano Y.
[Rinshō ketsueki] The Japanese journal of clinical hematology 53 ( 11 ) 1898 - 1905 2012.11
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：[Rinshō ketsueki] The Japanese journal of clinical hematology
Two consecutive treatment protocols, NHL-89 and NHL-96, for pediatric diffuse large cell lymphoma (DLC) and lymphoblastic lymphoma (LBL) were conducted between March 1989 and December 2004 by Kyushu-Yamaguchi Children's Cancer Study Group. Forty-two patients (DLC: 15, LBL: 27) and 34 patients (DLC: 8, LBL: 26) were enrolled in NHL-89 and NHL-96, respectively. DLC patients received induction therapy of high-dose methotrexate (MTX) followed by repeated administration of intermediate MTX. LBL patients received a 4-drug induction followed by intensification, consolidation with cranial radiotherapy (15 to 24Gy), and maintenance. The maintenance phase consisted of multiple drug treatment; including prednisolone, vincristine, cyclophosphamide, and 6-mercaptopurine. With a median follow-up of 150 months for NHL-89 and 90.5 months for NHL-96, the estimated event-free survival at 5 years are 76.2±6.6% and 67.7±8.0%, respectively. Both studies improved the prognosis of DLC and LBL over our previous study of NHL-858.
-
Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan Reviewed
Matsunaga T, Yamashita K, Kubuki Y, Toyama T, Imataki O, Maeda K, Kawano N, Satou S, Kawano H, Ishizaki J, Yoshida S, Kameda T, Sasaki T, Sekine M, Kamiunten A, Taniguchi Y, Hidaka T, Katayose K, K-Shimoda H, Shide K, Yamamoto S, Moritake H, Nunoi H, Maki
International Journal of Hematology 96 ( 3 ) 342 - 349 2012.9
Language：English Publishing type：Research paper (scientific journal)
-
Taga T., Saito A., Kudo K., Tomizawa D., Terui K., Moritake H., Kinoshita A., Iwamoto S., Nakayama H., Takahashi H., Tawa A., Shimada A., Taki T., Kigasawa H., Koh K., Adachi S.
Blood 120 ( 9 ) 1810 - 1815 2012.8
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Blood
Myeloid leukemia in Down syndrome (ML-DS) is associated with good response to chemotherapy and favorable prognosis. Because little research has been focused on refractory/relapsed (R/R) cases, we conducted a retrospective analysis for R/R ML-DS. Among ML-DS patients diagnosed between 2000 and 2010 in Japan, 26 relapsed (25 in the BM and 1 in the skin), and 3 refractory patients were enrolled. The male/female ratio was 18/11. The median age at initial diagnosis of ML-DS was 2 years, and the median time to relapse was 8.6 months. Each patient initially had been treated with ML-DS-specific protocols. Thirteen of the 26 patients achieved complete remission with various kinds of reinduction chemotherapies; 2 of 8 survived without further recurrence after receiving allogeneic hematopoietic stem cell transplantation, and 4 of 5 maintained complete remissions with chemotherapy alone. Treatment failures mostly were associated with disease progression rather than treatment-related toxicities. The 3-year OS rate was 25.9% ± 8.5%. A longer duration from initial diagnosis to relapse was a significant favorable prognostic factor (P < .0001). We conclude that clinical outcome for patients with R/R ML-DS generally are unfavorable, even in those receiving hematopoietic stem cell transplantation. Novel methods to identify poor prognostic factors for ML-DS are necessary. © 2012 by The American Society of Hematology.
-
The Perceived Cancer Experience in Japanese Childhood Cancer Patients : A Qualitative Study Reviewed
TAKEI Yuko, OGATA Akiko, HIRAI Kei, OZAWA Miwa, MORITAKE Hiroshi, MANABE Atushi, SUZUKI Shin-ichi
52 ( 7 ) 638 - 645 2012.7
Language：Japanese Publishing type：Research paper (scientific journal)
-
Acute megakaryoblastic leukemia and severe pulmonary fibrosis in child with Down syndrome: Successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease Reviewed
Moritake H, Yamada A, Kimoto Y, Sawa D, Shimonodan H, Nunoi H
Am J Hematol 87 ( 4 ) 447 - 450 2012.4
Authorship：Lead author Publishing type：Research paper (scientific journal)
-
Acute megakaryoblastic leukemia and severe pulmonary fibrosis in child with Down syndrome: Successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease. Reviewed
Moritake H.＊, Yamada A., Kimoto Y., Sawa D., Shimonodan H., Nunoi H
American Journal of Hematology 87 ( 4 ) 457 - 450 2012.4
Language：English Publishing type：Research paper (scientific journal)
-
Concomitant transient erythroblastopenia of childhood with neonatal hepatitis. Reviewed
Moritake H, Hidaka F, Kamimura S, Kojima H, Shimonodan H, Nunoi H.
Pediatrics International 54 ( 1 ) 147 - 150 2012.2
Language：English Publishing type：Research paper (scientific journal)
-
Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies. Reviewed
Fujimoto T, Andoh T, Sudo T, Fujita I, Imabori M, Moritake H, Sugimoto T, Sakuma Y, Takeuchi T, Sonobe H, Epstein AL, Akisue T, Kirihata M, Kurosaka M, Fukumori Y, Ichikawa H.
Applied Radiation Isotopes 69 ( 12 ) 1713 - 1716 2011.12
Language：English Publishing type：Research paper (scientific journal)
-
Andoh T., Fujimoto T., Sudo T., Fujita I., Imabori M., Moritake H., Sugimoto T., Sakuma Y., Takeuchi T., Kawabata S., Kirihata M., Akisue T., Yayama K., Kurosaka M., Miyatake S., Fukumori Y., Ichikawa H.
Applied Radiation and Isotopes 69 ( 12 ) 1721 - 1724 2011.12
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Applied Radiation and Isotopes
Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of 10 B (45-74ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of l-BPA-fructose complex (500mg BPA/kg). © 2011 Elsevier Ltd.
-
C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC Reviewed
Moritake H, Shimonodan H, Marutsuka K, Kamimura S, Kojima H, Nunoi H
Am J Hematol. 86 ( 1 ) 75 - 78 2011.1
Authorship：Lead author Publishing type：Research paper (scientific journal)
-
Moritake H., Shimonodan H., Marutsuka K., Kamimura S., Kojima H., Nunoi H.
American Journal of Hematology 86 ( 1 ) 75 - 78 2011.1
Language：English Publishing type：Research paper (scientific journal)
-
P1-12 小児がん患者における病気のとらえ方と退院後の困難の関連性の検討(一般演題(ポスター発表),切れる最新の理論と途切れない地道な実践) Reviewed
武井 優子, 尾形 明子, 小澤 美和, 盛武 浩, 真部 淳, 平井 啓, 鈴木 伸一
日本行動療法学会大会発表論文集 ( 36 ) 164 - 165 2010.12
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：一般社団法人日本認知・行動療法学会
-
Randomized trial to compare LSA2L2 type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia. 共著 Reviewed
Nagatoshi Y, Moritake H, 他
Pediatr. Blood Cancer 55 ( 2 ) 239 - 247 2010.8
Language：English Publishing type：Research paper (scientific journal)
-
Cytomagalovirus infection mimicking juvenile myelomonocytic leukemia showing hypersensitivity to granulocyte-macrophage colony stimulating factor.（共著） Reviewed
Moritake H. 他
Pediatric Blood & Cancer 53 ( 7 ) 1324 - 1326 2009.12
Language：English Publishing type：Research paper (scientific journal)